Form 4: Royalty Pharma CEO to Acquire Shares, Disposes Derivatives

Royalty Pharma plc's CEO, Pablo G. Legorreta, reported a future acquisition of Class A Ordinary Shares from an equity award settlement and a disposition of convertible derivative interests.

Summary

• Pablo G. Legorreta, CEO and Chairman of the Board of Royalty Pharma plc, reported a planned acquisition of 21,901 Class A Ordinary Shares on August 6, 2025.
• This acquisition is exempt under Rule 16b-3 and is in connection with the settlement of Equity Performance Awards.
• The transaction is made pursuant to a Rule 10b5-1(c) pre-planned contract for the purchase or sale of equity securities.
• Following this planned transaction, Mr. Legorreta will directly own 904,396 Class A Ordinary Shares.
• Indirect beneficial ownership of Class A Ordinary Shares includes 460,139 by Legorreta Investments LLC, 123,310 by IRRA, 118,500 by SEP/IRA, 1,040,410 by Legorreta Children 2002 Trust, 901,590 by GST-Exempt Legorreta 2012 Family Trust, 41,306 by GST-Exempt Legorreta 2020 Family Trust, 6,930 by Spouse, 292,190 by Tata MC 35 Ltd., 10,000 by Son, 10,000 by Daughter, and 600,000 by Legorreta 2023 SR Trust.
• The filing also reported a disposition of 60,000 LP interests in RPI US Partners 2019, LP on August 8, 2025.
• Each LP interest in RPI US Partners 2019, LP can be exchanged for ten Class B Interests in Royalty Pharma Holdings Limited, which in turn can be exchanged for one Class A Ordinary Share of the Issuer, meaning the 60,000 LP interests are convertible into 600,000 Class A Ordinary Shares.
• The filing explicitly states that no limited partnership interests were being exchanged by the Reporting Person in connection with this reported disposition.
• Following this derivative transaction, Mr. Legorreta directly beneficially owns 692,701 LP interests in RPI US Partners 2019, LP, with additional indirect holdings through Legorreta Investments LLC (3,707,488), Legorreta Investments II LLC (1,832,363), and Spouse (147,014).

Sentiment

Score: 6

Explanation: The filing presents a mixed signal. The planned future acquisition of Class A shares by the CEO is a positive indicator of management's alignment and confidence. However, the reported disposition of a substantial number of convertible derivative interests, even if not an exchange for shares, represents a reduction in potential future equity exposure for the CEO. Overall, slightly positive due to the direct share acquisition.

Positives

• CEO Pablo G. Legorreta is set to acquire 21,901 Class A Ordinary Shares on August 6, 2025, through the settlement of Equity Performance Awards, indicating continued alignment with shareholder interests.
• The planned acquisition is part of a Rule 10b5-1(c) plan, demonstrating a structured and pre-determined approach to equity management.

Negatives

• A disposition of 60,000 LP interests in RPI US Partners 2019, LP occurred on August 8, 2025, which are convertible into 600,000 Class A Ordinary Shares.
• While the filing states these derivative interests were not exchanged by the reporting person for Class A shares, this disposition represents a reduction in the CEO's potential future equity exposure through convertible securities.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The reporting person's indirect beneficial ownership of Class A Ordinary Shares is held through various entities and trusts, including Legorreta Investments LLC, IRRA, SEP/IRA, Legorreta Children 2002 Trust, GST-Exempt Legorreta 2012 Family Trust, GST-Exempt Legorreta 2020 Family Trust, Tata MC 35 Ltd., Legorreta 2023 SR Trust, and directly by Spouse, Son, and Daughter. Similar indirect holdings apply to derivative securities through Legorreta Investments LLC, Legorreta Investments II LLC, and Spouse.

Stakeholder Impact

• Shareholders: The planned acquisition of shares by the CEO indicates continued alignment of management's interests with those of shareholders, potentially boosting investor confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

The filing presents a mixed signal. The planned future acquisition of Class A shares by the CEO through an equity award settlement is a positive indicator of management's alignment and confidence in the company's future. However, the reported disposition of a substantial number of convertible derivative interests, even if not an exchange for shares, represents a reduction in potential future equity exposure for the CEO. Given these offsetting factors, a 'hold' recommendation is appropriate, as the filing does not provide a clear strong directional signal for investment decisions, but offers positive insights into insider confidence.

Keywords

Royalty Pharma, RPRX, SEC Form 4, Insider Transaction, Equity Award, CEO Shareholding, Beneficial Ownership, Derivative Securities